JP2019535785A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535785A5 JP2019535785A5 JP2019528489A JP2019528489A JP2019535785A5 JP 2019535785 A5 JP2019535785 A5 JP 2019535785A5 JP 2019528489 A JP2019528489 A JP 2019528489A JP 2019528489 A JP2019528489 A JP 2019528489A JP 2019535785 A5 JP2019535785 A5 JP 2019535785A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- insulin
- subject
- mace
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 17
- 102000004877 Insulin Human genes 0.000 claims 9
- 108090001061 Insulin Proteins 0.000 claims 9
- 229940125396 insulin Drugs 0.000 claims 9
- 238000011282 treatment Methods 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 3
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- 206010027525 Microalbuminuria Diseases 0.000 claims 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 2
- 210000003423 ankle Anatomy 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 229960004225 insulin degludec Drugs 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 201000001474 proteinuria Diseases 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 208000037804 stenosis Diseases 0.000 claims 2
- 230000036262 stenosis Effects 0.000 claims 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 108010057186 Insulin Glargine Proteins 0.000 claims 1
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 claims 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 230000008321 arterial blood flow Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 229960001089 dobutamine Drugs 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 108010050259 insulin degludec Proteins 0.000 claims 1
- 229960002869 insulin glargine Drugs 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 238000012633 nuclear imaging Methods 0.000 claims 1
- 239000003538 oral antidiabetic agent Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16200906 | 2016-11-28 | ||
| EP16200906.2 | 2016-11-28 | ||
| EP17174682.9 | 2017-06-07 | ||
| EP17174682 | 2017-06-07 | ||
| PCT/EP2017/080600 WO2018096162A1 (en) | 2016-11-28 | 2017-11-28 | Insulin degludec in cardiovascular conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535785A JP2019535785A (ja) | 2019-12-12 |
| JP2019535785A5 true JP2019535785A5 (https=) | 2020-12-17 |
| JP7193455B2 JP7193455B2 (ja) | 2022-12-20 |
Family
ID=60937677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528489A Active JP7193455B2 (ja) | 2016-11-28 | 2017-11-28 | 心血管状態におけるインスリンデグルデク |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11278596B2 (https=) |
| EP (1) | EP3544683A1 (https=) |
| JP (1) | JP7193455B2 (https=) |
| CN (1) | CN110022935A (https=) |
| MA (1) | MA46897A (https=) |
| WO (1) | WO2018096162A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11278596B2 (en) | 2016-11-28 | 2022-03-22 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| TWI797133B (zh) | 2017-06-09 | 2023-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | 用於經口投予的固體組成物 |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
| CN113773397B (zh) * | 2020-06-10 | 2023-10-20 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| GB0309154D0 (en) * | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| CA2531988C (en) | 2003-08-05 | 2016-06-28 | Novo Nordisk A/S | Novel insulin derivatives |
| JP2015512908A (ja) * | 2012-03-28 | 2015-04-30 | サノフイ | 基礎インスリン療法 |
| CN105188736A (zh) * | 2013-03-20 | 2015-12-23 | 诺和诺德股份有限公司 | 胰岛素给药方案 |
| EP2991672A1 (en) * | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| JP2019535791A (ja) | 2016-11-28 | 2019-12-12 | ノヴォ ノルディスク アー／エス | 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク |
| US11278596B2 (en) | 2016-11-28 | 2022-03-22 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
-
2017
- 2017-11-28 US US16/463,598 patent/US11278596B2/en active Active
- 2017-11-28 EP EP17825753.1A patent/EP3544683A1/en not_active Withdrawn
- 2017-11-28 CN CN201780073496.7A patent/CN110022935A/zh active Pending
- 2017-11-28 JP JP2019528489A patent/JP7193455B2/ja active Active
- 2017-11-28 MA MA046897A patent/MA46897A/fr unknown
- 2017-11-28 WO PCT/EP2017/080600 patent/WO2018096162A1/en not_active Ceased
-
2022
- 2022-02-08 US US17/667,223 patent/US12233114B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535785A5 (https=) | ||
| Deacon | A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials | |
| Filippatos et al. | SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses | |
| Strain et al. | Diabetes, cardiovascular disease and the microcirculation | |
| Herman et al. | Insulin therapy increases cardiovascular risk in type 2 diabetes | |
| Sloth-Nielsen et al. | Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis | |
| RU2768283C2 (ru) | Семаглутид при сердечно-сосудистых состояниях | |
| FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
| HRP20220058T1 (hr) | Sastavi i metode za smanjenje velikih neželjenih kardiovaskularnih događaja | |
| JP2016539164A5 (https=) | ||
| JP7193455B2 (ja) | 心血管状態におけるインスリンデグルデク | |
| Feng et al. | Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes | |
| JP2019535791A5 (https=) | ||
| Heusch et al. | Recruitment of inotropic reserve in “stunned” myocardium by the cardiotonic agent AR-L 57 | |
| CA3013532C (en) | Liraglutide in cardiovascular conditions | |
| Li et al. | New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure | |
| Sedrak et al. | Evolving role of double and triple therapy with GLP-1 receptor agonists in obesity and cardiovascular disease | |
| Bonadei et al. | Ivabradine during cardiogenic shock: A clinical case and review of the literature | |
| Felker et al. | Heart failure as a consequence of ischemic heart disease | |
| Breite et al. | Changing Fields-Diabetes Medications Invading the Cardiovascular Space | |
| KEITH et al. | RECESSION OF NEURORETINOPATHY DURING THE COURSE OF MALIGNANT HYPERTENSION: Its Occurrence in Fifteen Patients Who Did Not Receive Directed Therapy | |
| Khutsoane | Liraglutide, an incretin mimetic: drug trends | |
| Filippas-Ntekouan | Effect of SGLT-2 inhibitors on the serum and urine metabolome in patients with type 2 diabetes mellitus | |
| Rafi et al. | Comparison of Empagliflozin-Linagliptin with Empagliflozin-Metformin Combination Therapy in Assessing Cardiovascular Profile and Anemia in Type 2 Diabetic Patients | |
| Sharma | Glucagon-like Peptide-1 Analogs |